Asia On The Move: BMS Names New China Head, Hospira Appoints Japan CEO
This article was originally published in PharmAsia News
Executive Summary
Following J&J, Eli Lilly and other Big Pharma firms, BMS installs new leadership in China, and Wuxi board director and audit committee chairwoman resigns. Meanwhile, Hospira hires Mundipharma executive to head its operation in Japan, and personnel changes take place in Bayer Yakuhin and China Resources Pharma Group.